Navigation Links
For Treatment of Irritable Bowel Syndrome, Linaclotide Will Emerge as the Market Leader and Will Achieve Blockbuster Status in 2019
Date:12/16/2010

BURLINGTON, Mass., Dec. 16, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its superb efficacy, acceptable safety profile and anticipated launch in all major markets, Ironwood/Forest/Almirall/Astellas's linaclotide will emerge as the market leader for the treatment of irritable bowel syndrome (IBS). In 2019, linaclotide will garner blockbuster sales of $1.1 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Although Sucampo/Takeda/Abbott's Amitiza was the IBS drug market leader in 2009, the drug's limited efficacy, loss of patent protection and competition from linaclotide will cause Amitiza's sales to drop sharply through 2019.

The findings from the Pharmacor topic entitled Irritable Bowel Syndrome, which will publish later this month, reveal that the overall IBS drug market will expand at a 14 percent annual rate from 2009 to 2019, owing to the market entry of much-needed first-in-class therapies.

The findings also reveal that, because of the heterogeneity of IBS and the high rate of generic penetration, the IBS therapy market is highly fragmented and underserved. The lack of prescription therapies that can address more than one symptom of the disease means that physicians and patients resort to using multiple drugs, many of which are inadequate at controlling motility or pain symptoms associated with IBS. Additionally, owing to the combination of high prevalence and low diagnosis rates, substantial commercial potential exists for the development of drugs that target this indication.  

"IBS is a highly prevalent chronic condition in the world's major pharmaceutical markets, but the lack of a biochemical or histological marker for positive diagnosis and incomplete understanding of the disease's pathophysiology and etiology have resulted in low diagnosis and treatment rates," said Decision Resources Analyst Iva Holder, Ph.D. "The limited number of efficacious treatment options suggests significant opportunity for new IBS therapies."

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Receives FDA Clearance for the CyberKnife® Systems Lung Optimized Treatment
2. Use of Vitamin K Antagonists in the Treatment of Atrial Fibrillation is Driven by the Availability of an Oral Formulation, Cost and Widespread Inclusion on Guidelines and Formularies
3. MHRA Issues Notice of Acceptance for Phase 3 Trial of GALNS for the Treatment of MPS IVA
4. ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
5. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
6. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
7. Physiotherapy Associates Announces New Multiple Sclerosis Specialty Treatment Program
8. Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020
9. Cancer Treatment Centers Oncology Information System Options Expand with New MOSAIQ Connectivity
10. Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020
11. Reportlinker Adds Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... Aug. 8, 2017   ... diluted (GAAP) loss per share from continuing operations ... revenues increased 16 percent to $110 million ... 27 percent to $161 million ... from continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 19, 2017 , ... Parker at Stonegate, ... over 1,000 passionate employees, caregivers, volunteers, thought leaders, researchers, educators and partners leading ... it was time to refresh the carpeting with the goal of maintaining the ...
(Date:8/18/2017)... , ... ... ... For Immediate Release                Contact: ... Shows Young Women Seek Sex and Relationship Advice from their ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... liquid handling handheld devices. Through an educational webinar, they will present the line ... a chance to learn how easy you can automate everyday pipetting tasks. , ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning assistance that serves communities throughout southern Florida, is working to ... provide scholarship assets to children from low income families. , The Take Stock ...
(Date:8/18/2017)... Raton, Fl (PRWEB) , ... August 18, 2017 ... ... largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy and ... associated with hormone imbalance and conditions of aging, such as menopause, andropause, thyroid ...
Breaking Medicine News(10 mins):